Every 8-K that GMR Solutions Inc. (GMRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GMRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMRS filings page.
GMR Solutions Inc. (GMRS) refinanced Global Medical Response, Inc.’s existing first lien Term Loan B facility as part of a repricing transaction, lowering the applicable interest margin from SOFR +3.25% to SOFR +2.75%, a reduction of approximately 50 basis points on a term loan now outstanding at about $2.7 billion.
In connection with the repricing, GMR voluntarily prepaid approximately $200 million of first lien term loans using cash on hand and estimates the changes will generate about $28 million in annual cash interest expense savings. Other than revised pricing and standard repricing provisions, the credit facility terms remain substantially unchanged.
The company also used approximately $32 million of cash on hand to satisfy payroll tax obligations tied to settlement of previously granted equity awards. On a June 30, 2026 pro forma basis, after these payments, GMR would have had roughly $188 million of cash and cash equivalents and about $4.27 billion of total debt, reflecting its strategy of using cash generation to reduce indebtedness and borrowing costs.
GMR Solutions Inc. (GMRS) announced that its subsidiary Global Medical Response, Inc. has obtained binding lender commitments for a repricing of its existing $2.9 billion first lien Term Loan B facility due October 2032. The transaction is expected to amend the term loan and close on or about September 17, 2026, subject to execution of definitive documentation and customary closing conditions.
In connection with the repricing, GMR plans to use approximately $200 million of cash on hand to voluntarily prepay outstanding borrowings, which would reduce the facility’s outstanding principal to about $2.7 billion. The applicable interest margin over SOFR is expected to decline from SOFR +3.25% to SOFR +2.75%, a reduction of roughly 50 basis points.
GMR expects this combination of repricing and partial repayment to generate about $28 million of annual cash interest expense savings, aligning with its stated capital allocation strategy to reduce indebtedness, lower borrowing costs, and support long-term deleveraging objectives. The company notes that these expectations are forward-looking and subject to customary closing risks.
GMR Solutions Inc. reported second-quarter 2026 net revenue of $1.49B, up 3.3% year over year, and $2.95B for the first half, up 4.9%. Despite revenue growth, the company posted a Q2 net loss of $28.3M versus prior-year net income of $80.8M, and first-half net income declined to $78.1M from $118.8M. Q2 Adjusted EBITDA was $284.5M, down 11.8%, while first-half Adjusted EBITDA was broadly flat at $589.6M, down 1.8%.
Management highlighted that the 2025 comparison benefited from $74.3M of favorable revenue estimate developments related to No Surprises Act claims. The company reaffirmed full-year 2026 guidance, targeting net revenue of $5.89B–$6.18B and Adjusted EBITDA of $1.135B–$1.195B, with cash used for net capital expenditures and aircraft financing expected at 5.1%–5.3% of net revenue. GMR generated $217.3M of operating cash in the first half, reduced long-term debt to $4.27B from $4.90B, redeemed $445.1M of redeemable preferred stock, and increased stockholders’ equity to $789.3M.
GMR Solutions Inc. filed an amended current report to update the role of director Jan Stern Reed. She had been appointed to the Board effective May 12, 2026 as Lead Independent Director without committee assignments disclosed at that time.
As of July 1, 2026, her preliminary committee assignments have been finalized. Ms. Reed is now serving as Chair of the Board’s Nominating, Corporate Governance and Compliance Committee and as a member of the Board’s Audit Committee, clarifying her governance responsibilities.
GMR Solutions Inc. filed a current report announcing that Dr. Amar Desai and Ellen Zane have been appointed to its Board of Directors, effective July 1, 2026. Both are classified as independent under New York Stock Exchange rules and will serve in staggered terms on the Company’s classified Board.
Ms. Zane will serve as a Class II director with a term ending at the 2028 annual meeting, while Dr. Desai will serve as a Class III director with a term ending at the 2029 annual meeting. Dr. Desai joins the Nominating, Corporate Governance and Compliance Committee, and Ms. Zane becomes chair of the Human Capital and Compensation Committee.
Each new director received an award of 9,972 restricted stock units under the 2026 Equity Incentive Plan, vesting on the first anniversary of appointment or earlier upon a Change in Control or certain termination events. The report notes there are no related-party transactions requiring disclosure and includes a press release highlighting their extensive healthcare leadership backgrounds.
GMR Solutions Inc. reported stronger first-quarter 2026 results and issued full-year 2026 guidance. Net revenue was $1,457,576, up from $1,367,407, a 6.6% increase, while net income rose to $106,336 from $38,024, a 179.7% gain.
Adjusted EBITDA increased to $305,052 from $278,061, up 9.7%. Net transport revenue per ambulance transport improved to $1,360 from $1,260, and same market revenue grew 7.9%. For full-year 2026, the company guided to net revenue of $5,890 to $6,180 (in millions) and Adjusted EBITDA of $1,135 to $1,195 (in millions).